Uncategorized

Morgan Stanley Maintains Underweight on Vertex, Lowers Price Target to $16

Morgan Stanley maintains Vertex (NASDAQ:VERX) with a Underweight and lowers the price target from $18 to $16.

byBenzinga Newsdesk

May 14, 2021

1 minute read

Morgan Stanley maintains Vertex (NASDAQ:VERX) with a Underweight and lowers the price target from $18 to $16.

Cukes, Cannabis, Peppers And Tomatoes: Village Farms Has The Full Salad, Cantor Fitzgerald Calls Co’s Q2 Earnings ‘Neutral But Constructive’

By Natan Ponieman

Today, 6:47 PM

Village Farms International (NASDAQ: VFF) (TSX: VFF) reported second-quarter financial

VFF

Plymouth Industrial REIT Q2 FFO $0.41 Up From $0.32 YoY, Sales $45.61M Beat $44.87M Estimate

By Benzinga Newsdesk

Today, 6:47 PM

Plymouth Industrial REIT (NYSE:PLYM) reported quarterly earnings of $0.41 per share. This is a 28.12 percent increase over earnings of $0.32 per share from the same period last year. The company reported quarterly sales

PLYM

Affimed Presents Findings From The Dose-Escalation Phase Of The First-In-Human Study Of AFM24 In Patients With EGFR-Positive Solid Tumors At AACR Annual Meeting

By Benzinga Newsdesk

Today, 6:47 PM

Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced data

AFMD

News

‘Rumor: Peloton Exploring Yearly Membership Price Option For The Peloton Digital App Subscription’ – PeloBuddy

By Benzinga Newsdesk

Today, 6:47 PM

Rumor: Peloton Exploring Yearly Membership Price Option for the Peloton Digital App Subscription - Peloton Buddy (pelobuddy.com) Peloton may be considering adding an annual membership option for the App-only

PTON

Morgan Stanley Maintains Underweight on Vertex, Lowers Price Target to $16

Related Posts

Cukes, Cannabis, Peppers And Tomatoes: Village Farms Has The Full Salad, Cantor Fitzgerald Calls Co’s Q2 Earnings ‘Neutral But Constructive’

Plymouth Industrial REIT Q2 FFO $0.41 Up From $0.32 YoY, Sales $45.61M Beat $44.87M Estimate

Affimed Presents Findings From The Dose-Escalation Phase Of The First-In-Human Study Of AFM24 In Patients With EGFR-Positive Solid Tumors At AACR Annual Meeting

‘Rumor: Peloton Exploring Yearly Membership Price Option For The Peloton Digital App Subscription’ – PeloBuddy